An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function. A prostate cancer journey can involve plenty of questions.

Prostate cancer treatments lead to higher long-term complication rates, emphasizing the need for informed decision-making regarding treatment options and side effects. Prostatectomy patients ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

Men with advanced prostate cancer undergoing local therapies such as radiation therapy or radical prostatectomy experience significantly more gastrointestinal and sexual issues, along with problems ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...

Using MRI instead of CT guidance to zero in on prostate tumors enables more precise delivery of SBRT and lowers side effect rates. MRI vs CT guidance reduces side effects from prostate cancer ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.